522 articles in this topic
A phase 3 trial in Japan finds oral orforglipron safe over one year across three doses, with mild-to-moderate GI side effects as the main concern.
Visceral fat dominates inflammatory protein signatures across blood sugar, blood pressure, and lipid traits — and a few hub proteins may be key drivers.
Blocking TLR2 signaling in aged mice reduces immune cell infiltration and fibrosis in insulin-producing islets, pointing to a new longevity target.
Antipsychotics like clozapine slash life expectancy by up to 20 years. GLP-1 and dual GIP/GLP-1 drugs may finally reverse that metabolic damage.
A large US cohort study finds tirzepatide and semaglutide carry identical asthma exacerbation risk, but tirzepatide reduces rescue inhaler use.
Combining cold thermogenesis with tirzepatide improves metabolism but doesn't accelerate weight loss beyond the drug alone, mouse study finds.
Experts propose renaming polycystic ovary syndrome to highlight cardiovascular and metabolic disease risk in hundreds of millions of women.
Adding a GLP-1 receptor agonist to finerenone plus SGLT2 inhibitor therapy preserved kidney function better in adults with type 2 diabetes and chronic kidney disease.
A Markov model analysis finds multi-step non-invasive screening for MASH in type 2 diabetics is cost-effective in the US and 5 European nations.
A large UK real-world study finds fenofibrate use is associated with significantly lower risk of severe diabetic eye disease compared to statins.
A newly identified role for UBE2N links mitochondrial cleanup to MASH protection, opening a potential metabolic disease target.
Patients on GLP-1 receptor agonists before knee replacement surgery had significantly lower rates of periprosthetic joint infection, especially diabetics.
